A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Clinical trial NCT02516410 · COMPLETED
Trial details
- NCT number
- NCT02516410
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-01
- Primary completion
- 2016-06-07
- Enrollment
- 168
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.